LBRX compared with ALT: revenue, margins and what each company keeps, and the suppliers and customers both name

LBRXLB Pharmaceuticals Inc

Mkt capRevenueRevenue

ALTAltimmune, Inc.

Mkt capRevenueRevenue

Compare

LBRXLB Pharmaceuticals Inc

ALTAltimmune, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LBRX

Reportimpliedrealized× implied

Q2 FY26—▼−1.13%—

May 13 '26—▲+3.79%—

Q1 FY26—▼−2.81%—

Q3 FY25—▼−4.26%—

ALT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.7%▼−2.33%×0.18

May 13 '26±8.2%▼−1.95%×0.23

= impliedLBRX realized, solidALT realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

Q1 FY26

±10.3%

▼−17.92%

×1.74

Q3 FY25±14.3%▲+5.07%×0.36

LBRXLB Pharmaceuticals Inc

39.74▼−1.02%· post 41.20

Mkt cap$1.2BRevenue—Revenue—

ALTAltimmune, Inc.

2.04▼−4.90%· post 2.07

ClosedOct 30 '26

Mkt cap$396.8MRevenue$26,000Q4 FY25Revenue$41,000FY25

Compare

ClosedOct 30 '26

LBRXLB Pharmaceuticals Inc

ALTAltimmune, Inc.

39.74▼−1.02%post 41.20

Price

2.04▼−4.90%post 2.07

$1.2B

Mkt cap

$396.8M

—

Revenue

$26,000Q4 FY25

—

Revenue

$41,000FY25

LBRX39.74▼−1.02%vsALT2.04▼−4.90%ClosedOct 30 '26